Alefacept

Alefacept
Clinical data
AHFS/Drugs.com Monograph
MedlinePlus a603011
Pregnancy
category
  • AU: C
  • US: B (No risk in non-human studies)
Routes of
administration
Intravenous, intramuscular
ATC code L04AA15 (WHO)
Legal status
Legal status
Pharmacokinetic data
Bioavailability 63% (IM)
Biological half-life ~270 hours
Identifiers
CAS Number 222535-22-0 YesY
DrugBank DB00092 YesY
ChemSpider none
UNII ELK3V90G6C YesY
KEGG D02800 YesY
ChEMBL CHEMBL1201571 N
Chemical and physical data
Formula C2306H3594N610O694S26
Molar mass 51801.1 g/mol
 NYesY (what is this?)  (verify)

Alefacept is a genetically engineered immunosuppressive drug. It was sold under the brand name Amevive in Canada, the United States, Israel, Switzerland and Australia. In 2011, the manufacturers made a decision to cease promotion, manufacturing, distribution and sales of Amevive during a supply disruption. According to Astellas Pharma US, Inc. (http://www.amevive.com/Patient%20letter.pdf), the decision to cease Amevive sales was neither the result of any specific safety concern nor the result of any FDA-mandated or voluntary product recall. On the other hand, usage of Amevive was associated with a certain risk of development systemic diseases such as malignancies. This drug was never approved for the European drug market.

Alefacept is used to control inflammation in moderate to severe psoriasis with plaque formation, where it interferes with lymphocyte activation.[1] It is also being studied in the treatment of cutaneous T-cell lymphoma and T-cell non-Hodgkin lymphoma.

Alefacept is a fusion protein: it combines part of an antibody with a protein that blocks the growth of some types of T cells.

Mechanism of action

The mechanism of action involves dual mechanisms. Alefacept inhibits the activation of CD4+ and CD8+ T cells by interfering with CD2 on the T cell membrane thereby blocking the costimulatory molecule LFA-3/CD2 interaction. Another mechanism is inducing apoptosis of memory-effector T lymphocytes. If the T cells were to become activated they would stimulate proliferation of keratinocytes resulting in the typical psoriatic symptoms. Therefore, alefacept leads to clinical improvement of moderate to severe psoriasis by blunting these reactions. Combinations of therapeutic modalities have been utilized to meet the challenge of difficult to treat psoriasis.[2]

Indications

Alefacept is indicated for the management of patients with moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. The concomitant use of low-potency topical corticosteroids was permitted during the treatment phase with alefacept and does not seem to pose any additional risks.

The drug was approved based upon studies involving 1,869 patients altogether with plaques covering at least 10% of body surface. Either 7.5 mg IV or 15 mg IM once a week were applied. The long-term results (reduction of at least 75% in pretreatment PASI scores) were 14% and 21%, respectively. Additional improvements ensuing after completion of the 12-week treatment phase or after completion of a second alefacept treatment were also seen. Often the remissions were maintained for 7 to 12 months after end of treatment.

Contraindications and precautions

Pregnancy and lactation

Pediatric patients

No clinical experience exists in patients under 18 years of age. The drug should therefore not be used in pediatric patients.

Side effects

Interactions

Necessary laboratory examinations

Dosage regimens

The standard dosage regimen is the weekly application of either 7.5 mg IV or 15 mg IM for a course of 12 weeks. The benefits and risks of repeated courses have not been explored in sufficient detail. Therapy should be conducted under the supervision of a physician experienced in the use of immunosuppressant agents.

Notes

  1. "New drugs". Australian Prescriber. 27 (101): 5. 2004. Retrieved 2006-08-20.
  2. Scheinfeld N. Therapy-resistant psoriasis treated with alefacept and subsequent narrow band ultraviolet B phototherapy with total clearing of psoriasis. Dermatol Online J. 2005;11(2)7. PMID 16150215

 This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".

External links

This article is issued from Wikipedia - version of the 9/13/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.